What are the side effects of gavreto?

What are the most common side effects of Gavreto?

According to the US Food and Drug Administration (FDA) and clinical trials, the most common side effects of Gavreto (pralsetinib) include [1]:

- Fatigue (36% of patients)
- Diarrhea (33% of patients)
- Nausea (28% of patients)
- Musculoskeletal pain (24% of patients)
- Constipation (22% of patients)
- Abdominal pain (20% of patients)
- Increased liver enzymes (18% of patients)
- Rash (17% of patients)
- Vomiting (16% of patients)
- Increased levels of liver enzymes or bilirubin (14% of patients)

What rare but serious side effects should I watch out for?

Gavreto carries a warning for potential liver damage or worsening of underlying liver disease. Other rare but serious side effects include [1]:

- Pancreatitis (inflammation of the pancreas)
- Gastrointestinal perforation (hernia in the intestines)
- Hypothyroidism (underactive thyroid)
- Thyroid nodules or cancer

How do I manage side effects with Gavreto?

Patients should inform their healthcare provider about any side effects. In some cases, side effects can be managed by adjusting the dose, temporarily stopping the medication, or adding other medications [1].

Is Gavreto a safe option for patients with certain conditions?

Gavreto is not recommended for patients with severe kidney disease, as it can accumulate in the body and cause liver damage [2]. Patients with pre-existing liver disease should be closely monitored for signs of liver damage.

Who should avoid Gavreto altogether?

Avoid Gavreto if you have:

- A severe allergic reaction to pralsetinib or any of its ingredients
- A history of bleeding disorders (e.g., hemophilia, von Willebrand disease)

Where can I find more information about Gavreto's side effects?

For more information on Gavreto's side effects, consult the FDA-approved patient medication guide, your healthcare provider, or DrugPatentWatch.com (https://drugpatentwatch.com/).

Sources:
[1] FDA-approved labeling for Gavreto (pralsetinib). (2022).
[2] ClinicalTrials.gov. (2021). A Study of the Efficacy and Safety of PDR001 (Pralsetinib) in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Harboring MET Exon 14 Skipping Mutations or MET Amplification.